Navidea Biopharmaceuticals Inc  

(Public, NYSEMKT:NAVB)   Watch this stock  
Find more results for OTC:NEOP
-0.010 (-1.16%)
Oct 28 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.85 - 0.88
52 week 0.26 - 2.06
Open 0.88
Vol / Avg. 93,928.00/928,152.00
Mkt cap 132.14M
P/E     -
Div/yield     -
EPS -0.14
Shares 155.75M
Beta 0.02
Inst. own 27%
Nov 2, 2016
Q3 2016 Navidea Biopharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Sep 27, 2016
Navidea Biopharmaceuticals Inc at Ladenburg Thalmann Healthcare Conference
Sep 22, 2016
Navidea Biopharmaceuticals Inc at Aegis Capital Growth Conference
Sep 7, 2016
Navidea Biopharmaceuticals Inc Enters into Letter of Intent with Cardinal Health for the Sale of Lymphoseek - Webcast
Aug 4, 2016
Q2 2016 Navidea Biopharmaceuticals Inc Earnings Release
Aug 4, 2016
Q2 2016 Navidea Biopharmaceuticals Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -123.85% -213.76%
Operating margin -10.75% -158.43%
EBITD margin - -135.70%
Return on average assets -255.64% -211.40%
Return on average equity - -
Employees 56 -
CDP Score - -


5600 Blazer Pkwy Ste 200
DUBLIN, OH 43017-7550
United States - Map
+1-614-7937500 (Phone)
+1-614-7937522 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company is developing multiple precision-targeted products based on the Manocept platform to help identify the sites and pathways of undetected disease. The Manocept platform is predicated on the ability to specifically target the CD206 mannose receptor expressed on activated macrophages. NAV5001 is an iodine-123 (I-123) radiolabeled single-photon emission computed tomography (SPECT) imaging agent being developed as an aid in the diagnosis of Parkinson's disease (PD) and other movement disorders, with potential use as a diagnostic aid in dementia. NAV4694 is a fluorine-18 (F-18) radiolabeled positron emission tomography (PET) imaging agent being developed as an aid in the diagnosis of patients with signs or symptoms of Alzheimer's disease (AD) and mild cognitive impairment (MCI).

Officers and directors

Eric K. Rowinsky M.D. Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Michael M. Goldberg M.D. President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Jed A. Latkin Chief Financial Officer, Interim Chief Operating Officer, Chief Accounting Officer
Age: 41
Bio & Compensation  - Reuters
Frederick O. Cope Ph.D. Senior Vice President - Pharmaceutical Research and Clinical Development, Chief Scientific Officer
Age: 69
Bio & Compensation  - Reuters
William J. Regan Senior Vice President - Global Regulatory Affairs and Quality Chief Compliance Officer
Age: 63
Bio & Compensation  - Reuters
Thomas J. Klima Senior Vice President and Chief Commercial Officer
Age: 43
Bio & Compensation  - Reuters
Anthony S. Fiorino M.D. Ph.D. Director
Age: 48
Bio & Compensation  - Reuters
Mark I. Greene M.D. Ph.D. Director
Age: 67
Bio & Compensation  - Reuters
Michael Rice Director
Age: 51
Bio & Compensation  - Reuters